LIVE POLIO IRUS VACCINES

Index
611
Chromatography
purification of vaccine, 87
Chumakov, M. P., paper 413-428, 576-587; 44, 88,
117, 240, 412, 429-432, 463, 464, 576, 577,
579, 580
Chumakova, M. Ya., 44
Chung Hin, Dr.- 478
Cincinnati
field trial, 591
isolates of vaccinees, 18, 24
population statistics, 591
virologic and serologic examinations, 377
Cincinnati, Board of Health, 591
Clayton, L. B. paper 435-444, 445-456
Clemmer Dorothy J., paper 144-155; 309
Cleveland, Department of Health, 303
Climate
conditions for successful immunization, 578
ecological behavior of polio, 603
CNS, see Central nervous system
Codeine
antibody activity diminished, 268
Cohen, Barbara, paper, 53-65
Cold mutants, see also Mutation
behavior in human beings, 101-108
Colombia
PASB Tissue Culture Laboratory in Cali, 569
Columbia SK virus
possible contaminant, 474
Como Village study, Minnesota, 161, 342, 351
Complement-fixation fraction
lost on DEAE column, 44
Complement-fixation tests, 243
Congenital abnormalities, and vaccination, 214-215
Congo
viruses isolated, serologically identical with CHAT,
66
Connaught Laboratories, 513
Contact transmission
better immunization, 421, 585
circulation, reduce to a minimum, 584
epidemiological importance, 485
failure to induce immune response, 152
frequently abortive, 156
in babies 6 months and older, 197
in institutionalized population, 100%, 156
in 16 of 50 families, 323
low morbidity, 490, 510
siblings exposed, 463
Type 1 and Type 3 viruses inhibited by Type 2
vaccine, 257
unreliable, 485, 496
Contaminants
Type 1 in Type 2 vaccine, 341
vacuolating virus common in monkey-kidney cultures,
85
Control groups
advantages, 505
external and internal, described, 486, 493
Control tests
Poland, 522
USSR, 580
Conversion rates
and seronegative index, 369, 566
by type, 33, 183, 272, 332, 339, 386, 400, 441, 443,
532, 538, 541, 559
comparison of, fed with natural rates, 381
criteria, 375
due to heterotypic responses, 122, 374
effect of Salk vaccination, 537
high, 113, 363
in children free from interfering wild viruses, 115
in prevaccination negatives, 332, 372, 574
in those infected with enteric viruses, 122
Lederle study group, 335
monovalent and trivalent compared, 338, 367, 568
significance at 1:4 level, 121, 371
with trivalent, Type 2 best, 568
Cooney, Marion K., paper 161-173, 341-354, 357-364
Cord-blood
and antibody response, 218, 320
collection technique, 315
duration of antibody excretion, 288
for prevaccination antibody determination, 215
Cord lesions
intensity lower in Sabin strains than Lederle-
Cox, 12
severe in chimps with d+ T+ isolates, 18
Cornely, Donald, paper 287-293
Corticosteroid drugs
reactions to chicken pox after treatment, 461
Costa Rica, 568
cases in children, 574
environmental factors and virus multiplication, 132
field trial, 113-120, 174-184, 561-573
map, 562
paralytic polio incidence by age, 570
vaccine stable in children by T and d marker tests,
118
Costa Rica, Ministry of Health, 569
Courtois, Ghislain, paper 466-473; 54
Covariation, markers and gene situation, 49
Cox, H. R., paper 31-37, 330-340; 8, 39, 67, 98, 117,
121, 124, 163, 174, 193, 199, 212, 214, 226,
275, 324, 327, 329, 341, 369, 371-375, 437,
575, 576, 579, 596, 598
Cox strains, see Vaccine, Attenuated, Lederle-Cox
Coxsackie virus, 246
interference, 421, 479, 571
Coxsackie
occurrence before vaccination, 535-537
sera examined, 535
Group A
A-4
associated with T- polio, 464
A-9, 241, 271, 273
Group B
B-1-5, 241, 271, 273
B-I, 257
B-2
cases in Franklin, La., 147
interference with Type 3 vaccine, 157
B-2 and B-3
infection during vaccination, 151